AMCP 2022: Zahra Mahmoudjafari of University of Kansas Health System Discusses CAR T-Cell Therapies in Managed Care

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.

Here’s what you missed this week on Managed Healthcare Executive.

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting factors.

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.

Juan Carlos Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), and Marissa Schlaifer, RPh, M.S., vice president of policy at Optum.